Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.

Name: Kaimen Rigor review — Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.
Item: Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.
Rating: 94
Author: Alpha1

Reilmann R, Feigin A, Rosser AE, Kostyk SK, Saft C, Cohen Y, Schuring H, Hand R, Tan AM, Chen K, Feng W, Navon-Perry L, Cruz-Herranz A, Syltevik C, Boot D, Squitieri F, Kayson E, Mehra M, Goldberg YP, Geva M, Hayden MR, PROOF-HD study investigators

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 1.75★ (Critical), 0 critical, 3 high issues for “Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.

Read full text (PMC)

DOI

10.1038/s41591-025-03920-3

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/b24a7338-e4ed-4320-abed-9e4b6b7a9075" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/b24a7338-e4ed-4320-abed-9e4b6b7a9075/badge" alt="Kaimen Rigor review — 1.75★ (Critical), 0 critical, 3 high issues for “Pridopidine in early-stage manifest Huntington&#39;s disease: a phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

5b4516faeb15f959b11e8f1896d8df4a90bbdfae7c6836d0df0e72703e695458

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.

Paper source

Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

1.75 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on the surrogate endpoints TFC and cUHDRS, which are clinical rating scales but not hard clinical outcomes. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD or receptor occupancy) nor does it cite validated evidence linking these surrogates to long-term clinical outcomes. The claim of potential benefit is based on nominal trends in a subgroup, not on a validated surrogate-to-clinical link.
“The primary and key secondary endpoints, change in total functional capacity (TFC) and composite Unified Huntington’s Disease Rating Scale (cUHDRS) score at week 65, were not met in the overall population.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect sizes are small and not clinically meaningful: TFC difference of -0.18 (95% CI -0.49 to 0.14) and cUHDRS difference of -0.11 (95% CI -0.40 to 0.18), both not statistically significant. Subgroup analyses show nominal differences (e.g., cUHDRS Δ=0.46 at week 26) but these are not anchored to a minimal clinically important difference and are unadjusted for multiplicity.
“The TFC least-squares mean difference between pridopidine and placebo was −0.18 (95% confidence interval −0.49 to 0.14; P = 0.26). The cUHDRS least-squares mean difference between pridopidine and placebo was −0.11 (95% confidence interval −0.40 to 0.18; P =…”
Find in source
03Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
Pridopidine has the potential to address a critical unmet need in HD.
“Taken together, pridopidine has the potential to address a critical unmet need in HD.”
DiscussionFind in source
04Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Trial NCT03690193 was first submitted to ClinicalTrials.gov on 2018-08-01, after the registered study start date of 2013-12-03. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT03690193
reviewer’s wording

Findings by category

101ArithmeticNumerical inconsistencies 402OverreachOverstated conclusions 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit7 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 3 randomized controlled trial with rigorous design, comprehensive reporting of demographics and ethics, and appropriate statistical methods. The main weaknesses are minor reporting gaps: no explicit power analysis, no explicit outlier handling, a data availability statement that relies on a generic email rather than a named platform, and a few copyedit inconsistencies including a mismatched ClinicalTrials.gov URL and a p-value discrepancy.

Both reviewers classified the study as interventional (phase 3 RCT), and I adopt that classification. The evaluation covered all eight dimensions; several sub-criteria were not applicable (e.g., animal housing, cell line authentication) for this human drug trial. The statistics verification recomputed only 4 tests (all consistent); the rest of the statistical results were not machine-verified and should not be assumed correct. The citation check found no retracted or non-existent references.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

Overstated conclusions

4 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

7 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst medium

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior clinical trials (HART, MermaiHD, PRIDE-HD) and preclinical evidence for pridopidine's mechanism, acknowledging both strengths and weaknesses. The rationale linking the Sigma-1 receptor agonist activity to potential neuroprotection in HD is logically presented. Limitations of prior research, such as confounding by antidopaminergic medications, are addressed and motivate the sensitivity analysis.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on HD, pridopidine's mechanism, and previous clinical trials, and clearly links this to the study's objectives.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“Preclinical evidence demonstrates that pridopidine exerts neuroprotective effects through a multimodal action—reducing endoplasmic reticulum stress, promoting calcium homeostasis and stimulating neurotrophic-dependent restoration of synaptic plasticity.”

“These findings supported further evaluation of pridopidine in PROOF-HD (Pridopidine-Outcome-on-Function), a global phase 3, randomized, double-blind, placebo-controlled trial in early adult-onset HD.”

Introduction ¶3Find in source

paraphrase[Introduction, paragraph 4]

“However, given their known side effects, such as parkinsonism, sedation and cognitive impairment, which may confound trial outcomes, a sensitivity analysis was conducted in a subgroup of participants who remained off ADMs.”

PASSReviewer 2· 95% conf

The paper establishes a clear scientific premise by citing prior work on HD, the limitations of current treatments, and the rationale for targeting Sigma-1 receptor with pridopidine.

Evidence

“Clinical trials show oral pridopidine is well-tolerated with a benign safety profile – and may have the potential to preserve functional capacity, cognition and motor function in HD – . In early clinical studies, including the HART and MermaiHD trials ,,, , motor-related endpoints were primary outcomes but were not met.”

Main, paragraphs 2-4Find in source

“Symptomatic treatments exist, but therapies to modify disease progression are urgently needed ,, .”

Main, paragraph 1Find in source

“However, given their known side effects, such as parkinsonism, sedation and cognitive impairment, which may confound trial outcomes ,,, , a sensitivity analysis was conducted in a subgroup of participants who remained off ADMs”

Main, paragraph 5Find in source

Randomization was 1:1, stratified by baseline HD stage and antipsychotic use, with allocation concealed. Blinding is described (double-blind, indistinguishable capsules). A power analysis is not explicitly reported in the text, but the sample size (499) is typical for a phase 3 trial; the absence of an explicit power calculation is a minor gap. Inclusion/exclusion criteria are implied (TFC 7-13 at screening). Missing data were handled via multiple imputation (MNAR) for ITT and observed-case MMRM for mITT. The trial is registered (NCT04556656).

Sub-criteria

controlsN/A

power analysisNOT REPORTED

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with stratification, a pre-specified analysis plan, and appropriate handling of missing data and analysis populations.

Evidence

“Randomization was stratified based on baseline HD stage (HD1 TFC 11–13 versus HD2 TFC 7–10) and antipsychotic use at baseline (yes or no). The randomization sequence was generated by the Sponsor’s designated statistical team, and allocation was concealed from site investigators, participants and study staff throughout the trial.”

MethodsFind in source

“Participants in the active arm received pridopidine at the clinically recommended dose of 45 mg bid orally administered as hard gelatin capsules, whereas those in the placebo arm received indistinguishable matching placebo capsules.”

MethodsFind in source

“For ITT analysis: Missing data were imputed using multiple imputations (MI) under the assumption of missing not at random (MNAR).”

Table 2Find in source

PASSReviewer 2· 95% conf

The study design is rigorous: randomized, double-blind, placebo-controlled, with pre-specified inclusion/exclusion criteria, a power analysis, and a clear description of the analysis populations.

Evidence

MethodsFind in source

“aimed to evaluate the efficacy and safety of pridopidine at a dose of 45 mg bid in participants with a TFC score range of 7–13 at screening.”

MethodsFind in source

Sex is reported (51.9% female in ITT). Age is reported (mean 52.5 years). Demographics include age, sex, race/ethnicity is not explicitly reported but is not required for a global trial. Disease characteristics (CAG repeat length, TFC, TMS, etc.) are extensively reported. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline disease characteristics are comprehensively reported, including age, sex, CAG repeat length, disease stage, and functional scores.

Evidence

“Age (years), mean (s.d.) | 52.6 (11.37) | 52.4 (11.92)”

Table 1Find in source

“Female, n (%) | 126 (51.0) | 129 (53.3)”

Table 1Find in source

PASSReviewer 2· 95% conf

Demographics and baseline disease characteristics are comprehensively reported for the human participants, including age, sex, and disease stage.

Evidence

“In the ITT population, the mean (s.d.) age was 52.5 (11.7) years, CAG repeat length was 43.9 (3.54) and 51.9% of participants were female.”

Results ¶2Find in source

“Age (years), mean (s.d.) | 52.6 (11.37) | 52.4 (11.92)”

Table 1Find in source

“The disease stage distribution showed 41.3% of participants were at stage HD1 (TFC 11–13) and 58.7% were at stage HD2 (TFC 7–10).”

Results ¶2Find in source

The paper names multiple IRBs/IECs (e.g., Western Institutional Review Board, Comité de Protection des Personnes Ile de France VI) and states that the protocol was approved. Written informed consent is explicitly mentioned. Regulatory compliance with the Declaration of Helsinki and ICH-GCP is stated.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are thoroughly documented: named IRBs/IECs approved the protocol, written informed consent was obtained, and compliance with the Declaration of Helsinki and GCP is stated.

Evidence

paraphrase[Methods, Ethical considerations]

“Ethical approvals were obtained from IRBs and IECs at each participating site, including but not limited to the Western Institutional Review Board (USA), Comité de Protection des Personnes Ile de France VI (France), Ethik-Kommission der Ärztekammer Hamburg (Germany)...”

“Written informed consent was obtained from all participants before any study-specific procedures were conducted.”

MethodsFind in source

paraphrase[Methods, Ethical considerations]

“This trial was conducted in accordance with the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines, as well as the International Council for Harmonisation guidelines for Good Clinical Practice.”

PASSReviewer 2· 95% conf

Ethical approvals are adequately reported: the study was conducted in accordance with the Declaration of Helsinki and ICH-GCP, with named IRBs/IECs and informed consent obtained.

Evidence

MethodsFind in source

paraphrase[Methods, Ethical considerations]

“Written informed consent was obtained from all participants before any study-specific procedures were conducted.”

MethodsFind in source

The investigational drug, pridopidine, is identified by name, dose (45 mg bid), and formulation (hard gelatin capsules). Placebo is described as indistinguishable matching capsules. No antibodies, cell lines, or organisms are used. Software (SAS v.9.4) is identified. The study is a clinical trial of a drug, so the investigational product is the key resource.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (pridopidine) is identified with dose and formulation; no other key biological/chemical resources are used.

Evidence

paraphrase[Methods, Trial design]

“Participants in the active arm received pridopidine at the clinically recommended dose of 45 mg bid orally administered as hard gelatin capsules.”

“All statistical analyses were conducted using SAS v.9.4.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The investigational product (pridopidine) is identified with dose and regimen; no other key biological or chemical resources are used, making most sub-criteria not applicable.

Evidence

“Participants in the active arm received pridopidine at the clinically recommended dose of 45 mg bid orally administered as hard gelatin capsules”

MethodsFind in source

“All statistical analyses were conducted using SAS v.9.4.”

Statistical analysisFind in source

The primary analysis uses a mixed-effects model for repeated measures (MMRM), which is named. Assumptions are not explicitly verified but the MMRM is robust to certain violations. Exact p-values are reported for the primary endpoint (P = 0.27) and key secondary (P = 0.454). Effect sizes with 95% CIs are reported. Software (SAS v.9.4) is identified. Data presentation includes figures with individual data points (LSMean ± 95% CI) and per-group n. Mathematical plausibility checks are not applicable for continuous outcomes from a large trial.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described: MMRM for primary analysis, exact p-values and CIs reported, software identified, and data presentation follows clinical trial norms.

Evidence

paraphrase[Results, Primary outcome]

“The least-squares mean (LSMean) change was −0.95 (95% confidence interval (CI) −1.18 to −0.72) for placebo and −1.12 (95% CI −1.36 to −0.89) for pridopidine; difference −0.18 (95% CI −0.49 to 0.14; P = 0.27).”

“All statistical analyses were conducted using SAS v.9.4.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

Statistical methods are appropriate and well-described: MMRM is used for primary analysis, tests are named, effect sizes with CIs are reported, and software is identified. Exact p-values are reported for primary and key secondary endpoints.

Evidence

paraphrase[Methods, Statistical analysis]

“The primary analysis was performed using a maximum likelihood-based mixed-effects model for repeated measures (MMRM).”

“difference −0.18 (95% CI −0.49 to 0.14; P = 0.27)”

ResultsFind in source

“All statistical analyses were conducted using SAS v.9.4.”

Statistical analysisFind in source

The data availability statement describes a managed access process via email to the sponsor, with conditions and a timeframe. However, it does not name a specific repository or platform (e.g., Vivli, YODA) and relies on a request to a generic email address, which is considered 'reported_but_inadequate' per the guidelines. No custom code was developed, so code_sharing is not applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Data availability is well-described with a concrete managed-access process, and code availability is stated (no custom code).

Evidence

“Individual deidentified participant data (IDP), including data dictionaries, will be shared. Related documents including the study protocol, statistical analysis plan (SAP) and informed consent form template will also be available upon request and approval.”

Data availabilityFind in source

“a redacted version of the protocol and SAP are available at https://ghi-muenster.de/protocols/proof-hd and https://ghi-muenster.de/protocols/proof-hd-sap .”

Data availabilityFind in source

“No custom code was developed or used in this study.”

Data availabilityFind in source

WARNReviewer 2· 95% conf

A data availability statement is present but is inadequate because it only offers access 'on request' without a clear, concrete mechanism or platform, and no code was developed.

Evidence

“Requests for access to clinical trial data should be directed to the Sponsor, Prilenia Therapeutics, via email at: info@prilenia.com.”

Data availabilityFind in source

“No custom code was developed or used in this study.”

Data availabilityFind in source

The trial is registered (NCT04556656). Methods are detailed enough for replication. Limitations are explicitly discussed (ADM confounding, COVID-19, subgroup size). Conclusions are appropriately cautious, noting that primary endpoints were not met and subgroup findings are exploratory. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The manuscript is transparent: registered trial, detailed methods, limitations discussed, conclusions proportional, and funding/COI disclosed.

Evidence

“ClinicalTrials.gov identifier: NCT04556656”

AbstractFind in source

paraphrase[Discussion, paragraph 2]

“The trial was conducted during the COVID-19 pandemic, which impacted global healthcare access. As observed in other neuropsychiatric trials, a higher-than-expected use of ADMs was observed.”

paraphrase[Acknowledgements and Competing interests]

“This trial was sponsored and funded by Prilenia Therapeutics... A.C.-H., L.N.-P., A.M.T., M.G., Y.P.G., Y.C., R.H., K.C., W.F., C. Syltevik, D.B. and H.S. are employees of Prilenia Therapeutics B.V.”

PASSReviewer 2· 95% conf

The manuscript is transparent: methods are detailed, the trial is registered, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov identifier: NCT04556656”

AbstractFind in source

“Although no significant difference with treatment was observed in the off-ADM cohort for TFC, this cohort was smaller than anticipated, and consequently may have limited statistical power.”

Discussion ¶2Find in source

“This trial was sponsored and funded by Prilenia Therapeutics”

AcknowledgementsFind in source

Registered (3 IDs: ClinicalTrials.gov, EudraCT). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 66 references by DOI: 2 verified — 64 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

7 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 7 minor suggestions below.

7 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust overall, but an informed reader should weigh the minor reporting gaps: the lack of an explicit power analysis, the data availability mechanism relying on a generic email, and the internal inconsistencies (ClinicalTrials.gov URL mismatch, p-value discrepancy between Abstract and Results). These do not invalidate the findings but warrant attention; a correction or clarification from the authors would strengthen confidence.

1.
HIGHreporting
Correct the ClinicalTrials.gov URL in the Abstract to match the stated identifier NCT04556656 (currently points to NCT03690193).
The mismatched URL is an internal contradiction that could mislead readers and reviewers about the trial registration.
2.
HIGHstatistics
Reconcile the primary endpoint p-value: Abstract reports P = 0.26 while Results reports P = 0.27 for the same TFC endpoint; ensure both are consistent.
An internal inconsistency in the primary outcome p-value undermines reporting accuracy and could be flagged as an error.
3.
HIGHdata code
Enhance the Data availability statement to name a specific managed-access platform (e.g., Vivli, YODA) or a data access committee with a clear application process, rather than a generic email address.
A concrete data access mechanism is expected for a data-driven clinical trial; the current generic email is less transparent and may not meet journal requirements.
4.
MEDIUMreporting
Add an explicit a priori power analysis or sample size calculation in the Methods to justify the 499 participants, including assumed effect size, alpha, and power.
The absence of a power analysis is a reporting gap that reviewers may question, even though the sample size is typical for a phase 3 trial.
5.
MEDIUMstatistics
Describe how outliers were handled in the statistical analysis, or state that no outliers were excluded.
Explicit outlier handling is part of transparent statistical reporting and is currently not described.
6.
MEDIUMreporting
Add a statement on whether a reporting guideline (e.g., CONSORT) was followed, and if so, provide a reference or checklist.
Referencing CONSORT would enhance reporting transparency and is expected for a clinical trial.
7.
MEDIUMstatistics
Add a statement on the verification of statistical test assumptions (e.g., normality, sphericity) for the MMRM, or note that the method is robust to violations.
Explicitly addressing assumptions strengthens the statistical reporting and preempts reviewer concerns.
8.
MEDIUMreporting
Temper the claim 'Pridopidine has the potential to address a critical unmet need in HD' to reflect that primary endpoints were not met and the evidence is exploratory.
The claim is overstated relative to the primary outcome results; aligning it with the evidence avoids over-claiming.
9.
LOWcopyedit
Fix typo in Results, Safety and tolerability: change '82.8% of participants the pridopidine population' to '82.8% of participants in the pridopidine population'.
Missing preposition is a minor grammatical error that should be corrected for clarity.
10.
LOWcopyedit
Fix duplicate phrase in Results, Impact of pridopidine on functional decline (TFC): remove the repeated 'showed a'.
Repetition is a minor copyedit issue that detracts from readability.
11.
LOWcopyedit
Fix typo in Results, Safety and tolerability: change '3.6% of in the placebo group' to '3.6% in the placebo group'.
Extra word 'of' is a minor grammatical error.

Full text (93,300 chars · analyzed ~80%, head + tail)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.

Read full text (PMC)

DOI

10.1038/s41591-025-03920-3

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/b24a7338-e4ed-4320-abed-9e4b6b7a9075" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/b24a7338-e4ed-4320-abed-9e4b6b7a9075/badge" alt="Kaimen Rigor review — 1.75★ (Critical), 0 critical, 3 high issues for “Pridopidine in early-stage manifest Huntington&#39;s disease: a phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

5b4516faeb15f959b11e8f1896d8df4a90bbdfae7c6836d0df0e72703e695458

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

1.75 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on the surrogate endpoints TFC and cUHDRS, which are clinical rating scales but not hard clinical outcomes. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD or receptor occupancy) nor does it cite validated evidence linking these surrogates to long-term clinical outcomes. The claim of potential benefit is based on nominal trends in a subgroup, not on a validated surrogate-to-clinical link.
“The primary and key secondary endpoints, change in total functional capacity (TFC) and composite Unified Huntington’s Disease Rating Scale (cUHDRS) score at week 65, were not met in the overall population.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect sizes are small and not clinically meaningful: TFC difference of -0.18 (95% CI -0.49 to 0.14) and cUHDRS difference of -0.11 (95% CI -0.40 to 0.18), both not statistically significant. Subgroup analyses show nominal differences (e.g., cUHDRS Δ=0.46 at week 26) but these are not anchored to a minimal clinically important difference and are unadjusted for multiplicity.
“The TFC least-squares mean difference between pridopidine and placebo was −0.18 (95% confidence interval −0.49 to 0.14; P = 0.26). The cUHDRS least-squares mean difference between pridopidine and placebo was −0.11 (95% confidence interval −0.40 to 0.18; P =…”
Find in source
03Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
Pridopidine has the potential to address a critical unmet need in HD.
“Taken together, pridopidine has the potential to address a critical unmet need in HD.”
DiscussionFind in source
04Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Trial NCT03690193 was first submitted to ClinicalTrials.gov on 2018-08-01, after the registered study start date of 2013-12-03. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT03690193
reviewer’s wording

Findings by category

101ArithmeticNumerical inconsistencies 402OverreachOverstated conclusions 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit7 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

Overstated conclusions

4 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst medium

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on HD, pridopidine's mechanism, and previous clinical trials, and clearly links this to the study's objectives.

Evidence

paraphrase[Introduction, paragraphs 1-3]

Introduction ¶3Find in source

paraphrase[Introduction, paragraph 4]

PASSReviewer 2· 95% conf

The paper establishes a clear scientific premise by citing prior work on HD, the limitations of current treatments, and the rationale for targeting Sigma-1 receptor with pridopidine.

Evidence

Main, paragraphs 2-4Find in source

“Symptomatic treatments exist, but therapies to modify disease progression are urgently needed ,, .”

Main, paragraph 1Find in source

Main, paragraph 5Find in source

Sub-criteria

controlsN/A

power analysisNOT REPORTED

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with stratification, a pre-specified analysis plan, and appropriate handling of missing data and analysis populations.

Evidence

MethodsFind in source

“For ITT analysis: Missing data were imputed using multiple imputations (MI) under the assumption of missing not at random (MNAR).”

Table 2Find in source

PASSReviewer 2· 95% conf

The study design is rigorous: randomized, double-blind, placebo-controlled, with pre-specified inclusion/exclusion criteria, a power analysis, and a clear description of the analysis populations.

Evidence

MethodsFind in source

“aimed to evaluate the efficacy and safety of pridopidine at a dose of 45 mg bid in participants with a TFC score range of 7–13 at screening.”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline disease characteristics are comprehensively reported, including age, sex, CAG repeat length, disease stage, and functional scores.

Evidence

“Age (years), mean (s.d.) | 52.6 (11.37) | 52.4 (11.92)”

Table 1Find in source

“Female, n (%) | 126 (51.0) | 129 (53.3)”

Table 1Find in source

PASSReviewer 2· 95% conf

Demographics and baseline disease characteristics are comprehensively reported for the human participants, including age, sex, and disease stage.

Evidence

“In the ITT population, the mean (s.d.) age was 52.5 (11.7) years, CAG repeat length was 43.9 (3.54) and 51.9% of participants were female.”

Results ¶2Find in source

“Age (years), mean (s.d.) | 52.6 (11.37) | 52.4 (11.92)”

Table 1Find in source

“The disease stage distribution showed 41.3% of participants were at stage HD1 (TFC 11–13) and 58.7% were at stage HD2 (TFC 7–10).”

Results ¶2Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are thoroughly documented: named IRBs/IECs approved the protocol, written informed consent was obtained, and compliance with the Declaration of Helsinki and GCP is stated.

Evidence

paraphrase[Methods, Ethical considerations]

“Written informed consent was obtained from all participants before any study-specific procedures were conducted.”

MethodsFind in source

paraphrase[Methods, Ethical considerations]

PASSReviewer 2· 95% conf

Ethical approvals are adequately reported: the study was conducted in accordance with the Declaration of Helsinki and ICH-GCP, with named IRBs/IECs and informed consent obtained.

Evidence

MethodsFind in source

paraphrase[Methods, Ethical considerations]

“Written informed consent was obtained from all participants before any study-specific procedures were conducted.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (pridopidine) is identified with dose and formulation; no other key biological/chemical resources are used.

Evidence

paraphrase[Methods, Trial design]

“Participants in the active arm received pridopidine at the clinically recommended dose of 45 mg bid orally administered as hard gelatin capsules.”

“All statistical analyses were conducted using SAS v.9.4.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The investigational product (pridopidine) is identified with dose and regimen; no other key biological or chemical resources are used, making most sub-criteria not applicable.

Evidence

“Participants in the active arm received pridopidine at the clinically recommended dose of 45 mg bid orally administered as hard gelatin capsules”

MethodsFind in source

“All statistical analyses were conducted using SAS v.9.4.”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described: MMRM for primary analysis, exact p-values and CIs reported, software identified, and data presentation follows clinical trial norms.

Evidence

paraphrase[Results, Primary outcome]

“All statistical analyses were conducted using SAS v.9.4.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

Evidence

paraphrase[Methods, Statistical analysis]

“The primary analysis was performed using a maximum likelihood-based mixed-effects model for repeated measures (MMRM).”

“difference −0.18 (95% CI −0.49 to 0.14; P = 0.27)”

ResultsFind in source

“All statistical analyses were conducted using SAS v.9.4.”

Statistical analysisFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Data availability is well-described with a concrete managed-access process, and code availability is stated (no custom code).

Evidence

Data availabilityFind in source

“a redacted version of the protocol and SAP are available at https://ghi-muenster.de/protocols/proof-hd and https://ghi-muenster.de/protocols/proof-hd-sap .”

Data availabilityFind in source

“No custom code was developed or used in this study.”

Data availabilityFind in source

WARNReviewer 2· 95% conf

A data availability statement is present but is inadequate because it only offers access 'on request' without a clear, concrete mechanism or platform, and no code was developed.

Evidence

“Requests for access to clinical trial data should be directed to the Sponsor, Prilenia Therapeutics, via email at: info@prilenia.com.”

Data availabilityFind in source

“No custom code was developed or used in this study.”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The manuscript is transparent: registered trial, detailed methods, limitations discussed, conclusions proportional, and funding/COI disclosed.

Evidence

“ClinicalTrials.gov identifier: NCT04556656”

AbstractFind in source

paraphrase[Discussion, paragraph 2]

“The trial was conducted during the COVID-19 pandemic, which impacted global healthcare access. As observed in other neuropsychiatric trials, a higher-than-expected use of ADMs was observed.”

paraphrase[Acknowledgements and Competing interests]

PASSReviewer 2· 95% conf

The manuscript is transparent: methods are detailed, the trial is registered, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov identifier: NCT04556656”

AbstractFind in source

“Although no significant difference with treatment was observed in the off-ADM cohort for TFC, this cohort was smaller than anticipated, and consequently may have limited statistical power.”

Discussion ¶2Find in source

“This trial was sponsored and funded by Prilenia Therapeutics”

AcknowledgementsFind in source

Registered (3 IDs: ClinicalTrials.gov, EudraCT). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 66 references by DOI: 2 verified — 64 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

7 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 7 minor suggestions below.

7 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHreporting
Correct the ClinicalTrials.gov URL in the Abstract to match the stated identifier NCT04556656 (currently points to NCT03690193).
The mismatched URL is an internal contradiction that could mislead readers and reviewers about the trial registration.
2.
HIGHstatistics
Reconcile the primary endpoint p-value: Abstract reports P = 0.26 while Results reports P = 0.27 for the same TFC endpoint; ensure both are consistent.
An internal inconsistency in the primary outcome p-value undermines reporting accuracy and could be flagged as an error.
3.
HIGHdata code
Enhance the Data availability statement to name a specific managed-access platform (e.g., Vivli, YODA) or a data access committee with a clear application process, rather than a generic email address.
A concrete data access mechanism is expected for a data-driven clinical trial; the current generic email is less transparent and may not meet journal requirements.
4.
MEDIUMreporting
Add an explicit a priori power analysis or sample size calculation in the Methods to justify the 499 participants, including assumed effect size, alpha, and power.
The absence of a power analysis is a reporting gap that reviewers may question, even though the sample size is typical for a phase 3 trial.
5.
MEDIUMstatistics
Describe how outliers were handled in the statistical analysis, or state that no outliers were excluded.
Explicit outlier handling is part of transparent statistical reporting and is currently not described.
6.
MEDIUMreporting
Add a statement on whether a reporting guideline (e.g., CONSORT) was followed, and if so, provide a reference or checklist.
Referencing CONSORT would enhance reporting transparency and is expected for a clinical trial.
7.
MEDIUMstatistics
Add a statement on the verification of statistical test assumptions (e.g., normality, sphericity) for the MMRM, or note that the method is robust to violations.
Explicitly addressing assumptions strengthens the statistical reporting and preempts reviewer concerns.
8.
MEDIUMreporting
Temper the claim 'Pridopidine has the potential to address a critical unmet need in HD' to reflect that primary endpoints were not met and the evidence is exploratory.
The claim is overstated relative to the primary outcome results; aligning it with the evidence avoids over-claiming.
9.
LOWcopyedit
Fix typo in Results, Safety and tolerability: change '82.8% of participants the pridopidine population' to '82.8% of participants in the pridopidine population'.
Missing preposition is a minor grammatical error that should be corrected for clarity.
10.
LOWcopyedit
Fix duplicate phrase in Results, Impact of pridopidine on functional decline (TFC): remove the repeated 'showed a'.
Repetition is a minor copyedit issue that detracts from readability.
11.
LOWcopyedit
Fix typo in Results, Safety and tolerability: change '3.6% of in the placebo group' to '3.6% in the placebo group'.
Extra word 'of' is a minor grammatical error.

Full text (93,300 chars · analyzed ~80%, head + tail)Analyzed: Aug 15, 2026